Melanoma Clinical Trial
Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma
Summary
RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Interferon alfa may interfere with the growth of tumor cells. Giving azacitidine together with interferon alfa may be an effective treatment for melanoma.
PURPOSE: This phase I trial is studying the side effects and best dose of azacitidine when given together with interferon alfa in treating patients with metastatic melanoma.
Full Description
OBJECTIVES:
Primary
Determine the maximum tolerated dose (MTD) of azacitidine in combination with interferon alfa-2b in patients with metastatic melanoma.
Determine if the MTD of this regimen is biologically active in these patients.
Define and describe the toxicities associated with this regimen.
Secondary
Determine, preliminarily, the response in patients treated with this regimen.
Describe, preliminarily, the time to progression and overall survival of patients treated with this regimen.
OUTLINE: This is a dose-escalation study of azacitidine.
Patients receive azacitidine subcutaneously (SC) once daily on days 1-5 (week 1) followed by interferon alfa-2b SC 3 days a week in weeks 2-4. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of azacitidine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
PROJECTED ACCRUAL: A total of 12 patients will be accrued for this study.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Histologically confirmed metastatic melanoma
At least one lesion appropriate for 3 separate punch or core needle biopsies
Must have received and failed ≥ 1 prior systemic treatment for metastatic disease
PATIENT CHARACTERISTICS:
ECOG performance status 0-2
Bilirubin ≤ 1.5 times upper limit of normal (ULN)
AST and ALT < 2 times ULN
Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 60 mL/min
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
No known allergies to azacitidine, interferon alfa, benzyl alcohol, or mannitol
No uncontrolled infection
No known HIV positivity
No hepatitis B or hepatitis C infection
PRIOR CONCURRENT THERAPY:
See Disease Characteristics
At least 3 weeks since prior systemic therapy
More than 4 weeks since prior radiotherapy to target lesions with evidence of progression
No concurrent radiotherapy to target lesions
No concurrent oral or IV corticosteroids
Topical creams or ocular steroid drops are allowed
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
La Jolla California, 92093, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.